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Background: Primary antibody deficiencies (PADs) and anterior pituitary dysfunction are
both rare conditions. However, recent studies have remarkably reported the occurrence
of anterior pituitary dysfunction in PAD patients.
Methods: In this cross-sectional, single-center study we evaluated the prevalence
of endocrine disorders in adult PAD patients. Our study focused on common variable
immunodeficiency (CVID), immunoglobulin G (IgG) subclass deficiency (IgGSD), and
specific anti-polysaccharide antibody deficiency (SPAD). We assessed hormone levels,
performed provocative tests and genetic testing in a subset of patients by direct
sequencing of the nuclear factor kappa beta subunit 2 (NFKB2) gene and primary
immunodeficiency (PID) gene panel testing by whole exome sequencing (WES).
Results: Our results demonstrated that one out of 24 IgGSD/SPAD patients had
secondary hypothyroidism and three out of 9 men with IgGSD/SPAD had secondary
hypogonadism. Premature ovarian failure was observed in four out of 9 women
with CVID and primary testicular failure in one out of 15 men with CVID. In two
out of 26 CVID patients we found partial adrenal insufficiency (AI) and in one out
of 18 patients with IgGSD/SPAD secondary AI was found. Moreover, in one out
of 23 patients with CVID and in two out of 17 patients with IgGSD/SPAD severe
growth hormone deficiency (GHD) was found, while one patient with IgGSD/SPAD
showed mild GHD. Combined endocrine disorders were detected in two women
with CVID (either partial secondary AI or autoimmune thyroiditis with primary
hypogonadism) and in three men with IgGSD/SPAD (two with either mild GHD or
secondary hypothyroidism combined with secondary hypogonadism, and one man
with secondary AI and severe GHD). Genetic testing in a subset of patients did
not reveal pathogenic variants in NFKB2 or other known PID-associated genes.
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Conclusion: This is the first study to describe a high prevalence of both anterior
pituitary and end-organ endocrine dysfunction in adult PAD patients. As these endocrine
disorders may cause considerable health burden, assessment of endocrine axes should
be considered in PAD patients.
Keywords: common variable immunodefiencies, endocrine disorders, immunodeficiency, endocrine dysfunction,
hormones
INTRODUCTION
Primary antibody deficiencies (PADs) are the most
common primary immunodeficiencies and are characterized
by a B lymphocyte differentiation defect and an impaired
production of antigen-specific antibodies resulting in increased
risk of infections (1). PADs represent a heterogeneous spectrum
of conditions, including common variable immunodeficiency
(CVID), immunoglobulin G (IgG) subclass deficiency (IgGSD)
and specific anti-polysaccharide antibody deficiency (SPAD).
CVID is a heterogeneous group of disorders primarily
characterized by decreased serum IgG and IgA and/or IgM levels
and impaired response to immunization (2, 3). CVID is clinically
characterized by recurrent and severe infections, polyclonal
lymphoproliferation, hematological malignancies, autoimmune
diseases, and non-infectious granuloma formation in various
organs (2, 3). IgGSD is defined by a reduction in one or more
IgG subclasses (1–4), that may result in infectious diseases as well
because of poor antibody responses (2, 3). SPAD is characterized
by a reduced ability to produce antibodies against polysaccharide
antigens (2, 3). Monogenetic defects responsible for CVID have
been described in 2–10% of patients, while the genetic defects for
IgGSD/SPAD remain unknown to date (3, 4).
Over the past years it has become clear that other, non-
immunological comorbidities may occur in PAD patients.
Although endocrine disorders are not regularly observed and
reported in patients with PAD, recent studies suggest that
anterior pituitary dysfunction is more common in patients with
PAD than generally assumed.
Anterior pituitary dysfunction, with an estimated prevalence
of 1:2,000, is the partial or complete defect in anterior
pituitary hormone secretion and may result from pituitary or
hypothalamic diseases (5). In 1991, Tovo et al. (6) reported
the first case of a patient with CVID and the presence of
an isolated adrenocorticotropic hormone (ACTH) deficiency,
resulting in secondary adrenal insufficiency (AI) (dysfunction
of the anterior pituitary). Since then, several other cases of
CVID and secondary AI have been reported in literature (7–
21). Quentien et al. (9) demonstrated isolated ACTH deficiency
in four patients with CVID, including two siblings, and defined
this disease association as a deficit in anterior pituitary function
and variable immune deficiency (DAVID). Meanwhile, several
cases have reported additional anterior pituitary and end-organ
endocrine dysfunction in CVID patients. In particular, growth
hormone deficiency (GHD) due to anterior pituitary dysfunction
was repeatedly reported (2 patients with mild and 8 patients with
severe GHD) (7, 9, 11, 15, 16, 21–24). Other distinct anterior
pituitary defects and/or combined with endocrine end-organ
dysfunctions were reported (7, 9, 11, 13, 15, 16, 19, 21, 22,
24, 25). The most important characterized reported cases are
summarized in Table 1 (6–11, 14, 15, 17–25).
Increased insights in causative genetic defects in CVID could
potentially explain concomitant endocrine disorders. As an
example, Chen et al. (10) reported germline variants near the C-
terminal region in nuclear factor kappa beta subunit 2 (NFKB2)
in CVID patients with secondary AI. Several other groups have
also reported variants confined to the C-terminal region of
the NFKB2 gene that could cause combined endocrine- and
immunodeficiencies and these are summarized in Figure 1 (10,
12–16, 19–21, 26). It should be stressed that the NFKB signaling
has a multitude of diverse functions within the immune system,
and the hitherto published phenotypic observations of patients
affected by NFKB2mutations were highly heterogenic (21).
To our knowledge no studies have attempted to systematically
assess the prevalence of endocrine disorders in a cohort of PAD
patients. The aim of our study is to investigate the prevalence
of anterior pituitary and endocrine end-organ dysfunctions in
adult patients with PADs from a tertiary referral center in
the Netherlands.
METHODS
Patients and Ethics
In this single-center cross-sectional study, adult PAD patients
were prospectively enrolled between May 2014 and November
2017. All patients (n = 67) were recruited from the outpatient
clinics of the Department of Internal Medicine, Division of
Clinical Immunology of the Erasmus University Medical Center,
Rotterdam, the Netherlands. All CVID, IgGSD, and SPAD
patients fulfilled the International Union of Immunological
Societies (IUIS) expert committee diagnostic criteria (27). This
study was carried out in accordance with the recommendations
of the Medical Ethics Committee of the Erasmus University
MC, Rotterdam with written informed consent from all subjects.
All subjects gave written informed consent in accordance with
the Declaration of Helsinki. The protocol was approved by
the Medical Ethics Committee of the Erasmus University MC,
Rotterdam (MEC 2013-026, NL40331.078).
Hormonal Evaluation
Basal concentrations of anterior pituitary and endocrine end-
organ hormones were measured including: ACTH, fasting
cortisol, free thyroxine (FT4), thyroid-stimulating hormone
(TSH), GH, insulin-like growth factor I (IGF-I), prolactin,
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TABLE 1 | Described endocrine dysfunction in patients with CVID.
Patient no. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Age at endocrine
diagnosis (yr)
♀ 14 (6) ♀ 8 (7) ♂ 7 (8) ♀ 15 (9) ♀ 5 (9) ♂ 9 (9) ♂ 8 (9) ♀ 28
(10)
♀ 6 (10) ♂ 3 (10) ♂ 16
(10)
♀ 17
(11)
♀ 9 (12) ♂ 4 (13) ♀ 18
(14)
Familial relationship Full
sibling
of P7
Full
sibling
of P6
Mother
of P13,
14
Daughter
of P12,
full sibling
of P14
Son of
P12,
full
sibling
of P13
Endocrine
dysfunctions
PADS CVID CVID CVID CVID CVID CVID CVID CVID CVID CVID CVID CVID CVID CVID CVID
Secondary AI
Severe GHD
Secondary hypothyroidism
Mild GHD
Secondary hypogonadism
Primary hypogonadism
Autoimmune thyroiditis
Primary hypothyroidism
Hyperprolactinemia
Patient no. 16 17 18 19-33 34 35 36 37 38 39 40 41 42 43 44
Age at endocrine
diagnosis (yr)
♀ 8 (15) ♂ 7 (16) ♀ 5 (17) - (18) ♀ 11
(19)
♂ 7 (20) ♂ - (21) ♂ 8 (21) ♂ 1 (21) ♀ (21) ♀ - (22) ♂ - (22) ♀ 10
(23)
♀ 24
(24)
♀ 24
(25)
Familial relationship Full
sibling
of P7
Full
sibling
of P6
Mother
of P13,
14
Daughter
of P12,
full sibling
of P14
Son of
P12,
full
sibling
of P13
Endocrine
dysfunctions
PADS CVID CVID CVID CVID CVID CVID CVID CVID CVID CVID CVID CVID CVID CVID CVID
Secondary AI
Severe GHD
Secondary hypothyroidism
Mild GHD
Secondary hypogonadism
Primary hypogonadism
Autoimmune thyroiditis
Primary hypothyroidism
Hyperprolactinemia
This table summarized anterior pituitary and end-organ endocrine dysfunction in CVID patients described in literature (6–25). AI, adrenal insufficiency; GHD, growth hormone deficiency; yr, years.
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FIGURE 1 | This figure summarized reported germline variants confined to the C-terminal region of the NFKB2 gene in CVID patients with endocrine dysfunctions
(10, 12–16, 19–21, 26). NFKB2, nuclear factor kappa beta subunit 2.
follicle-stimulating hormone (FSH), luteinizing hormone (LH),
in women anti-mullerian hormone (AMH) and estradiol, and
in men Inhibin B, sex hormone-binding globulin (SHBG) and
testosterone. In patients who were on chronic corticosteroid
therapy and who were not able to temporarily discontinue use of
corticosteroids for at least 5 days, serum cortisol was not assessed.
In all cases with abnormal TSH and/or free thyroxine levels,
thyroid autoantibodies (i.e., anti-thyroid peroxidase; anti-TPO,
anti-thyroglobulin; anti-Tg and anti-TSH-receptor; anti-TSH-R)
were measured.
All blood samples were assessed at the routine Clinical
Chemistry Laboratory (AKC) of Erasmus MC. In case patients
were on intravenous immunoglobulin (IVIG) treatment, blood
samples were collected prior to the IVIG infusion. All
samples were collected during an apparent infection-free period,
additional serum CRP was measured using AfinionTM Analyzer
(Alere Ltd, Stockport, UK) to rule out acute endocrine disorders
secondary to current inflammation.
Serum ACTH, cortisol, FSH, LH, prolactin, SHBG and TSH
(Immulite 2000 XPi, Siemens AG), GH and IGF-I (IDS-iSYS;
Immunodiagnostic Systems Limited, Boldon, UK), estradiol
(Cobas e411, Roche Diagnostics GmbH) and free T4 (Vitros
ECI, Ortho Clinical Diagnostics, Rochester, NY) were analyzed
by automated immunoassays. IGF-I was interpreted according
to the sex and age-dependent ranges as defined by Bidlingmaier
et al. (28). Serum AMH (Beckman AMH gen II) and Inhibin
B (Beckman Inhibin B gen II) were manually determined by
ELISA. Testosterone was determined by liquid chromatography-
tandemmass spectrometry (PerkinElmer CHSTM MSMS Steroids
Kit on a Waters Xevo TQS). Furthermore, serum anti-TPO and
anti-TSH-R were measured with and in-house ELISA and anti-
Tg was assessed using the ImmunoCAP method (Phadia 250,
Uppsala, Sweden).
Provocative Testing
Provocative testing was performed at our inpatient clinic on
a separate occasion when AI and/or GHD was suspected or
when patients had another anterior pituitary deficiency. AI was
suspected in patients with a fasting basal serum cortisol <266
nmol/L. In patients with basal serum cortisol 266–550 nmol/L, AI
is not excluded. Therefore, basal serum cortisol was repeated in
these cases and when a second result was still below 550 nmol/L,
based on our assay-specific normative data, a provocative test was
performed. GHD is suspected in patients when IGF-I levels were
below−1 SDs according to Bidlingmaier et al. (28).
Insulin tolerance test (ITT) was used for the assessment of AI
or GHD. The ITTwas carried out before breakfast after overnight
fasting. Venous blood samples were drawn for assessment
of cortisol, ACTH, GH, and glucose before (−15min), and
at 0, 20, 30, 40, 60, and 90min after administration of i.v.
insulin. In patients in whom an ITT was contraindicated (i.e.,
history of coronary artery disease, seizures or stroke; age >
65 is a relative contraindication), an overnight metyrapone test
was performed. The test starts at day 1 at 8 a.m. with oral
administration of 750mg of metyrapone, followed by 6 doses
additional administration every 4 h. Serum cortisol and 11-
deoxycortisol were measured as described above at 8 a.m. at
day 2. Growth hormone releasing hormone (GHRH)-arginine
test was only performed in patients with isolated decreased
IGF-I levels or when ITT results remained inconclusive. The
GHRH-arginine test starts by administration of i.v. GHRH (1 µg
GHRH/kg bodyweight; BW), followed by a 30min continuous
infusion of 0.5 g arginine/kg BW followed by measurement
of GH at −15, 0, 5, 10, 15, 20, 30, 45, 60, 75 and 90min.
In patients who were not able to temporarily discontinue
use of corticosteroids for at least 5 days, provocative testing
was not performed. The biochemical tests and diagnostic
methods were performed in a specialized accredited laboratory
for endocrine diseases and confirmed by a senior neuro-
endocrinologist (S.N.).
Neuroradiological Imaging
Magnetic resonance imaging (MRI) of the pituitary was
performed according to standard operation procedures of the
department of neuroradiology of the Erasmus MC.
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Genetic Analysis
Direct Sanger sequencing of the two C-terminal coding exons
of the NFKB2 gene was performed in a selected group of PAD
patients with endocrine dysfunction (n = 16). We focused on
the NFKB2 gene expression based on previous reports (10, 12–
16, 19–21, 26) and its known function in both the immune and
endocrine systems. DNA was extracted from peripheral blood
samples using standard protocols. NFKB2 exon 22 and 23 were
PCR-amplified with TaqGoldTM (Life Technologies) followed
by direct sequencing on an ABI Prism 3130 XL fluorescent
sequencer (Applied Biosystems, The Netherlands). Sequences
were analyzed with CLC DNA workbench software (CLCBio,
Aarhus, Denmark) and compared to the NCBI reference
sequence (NG_033874).
Additionally, in eight patients PID gene panel testing
comprising over 250 PID-associated genes [range 274–367;
based on the IUIS classifications 2015 (29) and 2017 (3)
was performed using whole exome sequencing (WES). DNA
was enriched for the exome using the Agilent Sureselect
Clinical Research Exome V2 Capture Enrichment kit (Agilent
Technologies) and paired-end sequenced on the Illumina Hiseq
platform (GenomeScan, Leiden, the Netherlands). Using our
sequencing protocols, the average coverage of the exome is
∼50X. Reads were mapped to the genome with the BWA-MEM
algorithm (http://bio-bwa.sourceforge.net/) and variant calling
was performed by the Genome Analysis Toolkit HaplotypeCaller
(http://www.broadinstitute.org/gatk/). Detected variants in the
PID-associated genes were filtered and annotated with the
Cartagenia software package and classified with Alamut Visual.
Detailed information for each panel is listed in Table S1.
Statistical Analysis
Statistical analyses were performed using SPSS software (version
21 for Windows; SPSS Inc., Chicago, Illinois). Descriptive
statistics were used to summarize patient characteristics.
The non-parametric unpaired two-samples Wilcoxon test, the
Pearson chi-square tests or the Fisher’s exact test were used
to determine the significance of difference between CVID
and IgGSD/SPAD patients. We considered P-values of < 0.05
to be statistically significant, P-values were not corrected for
multiple comparisons.
RESULTS
Patient Characteristics
The baseline characteristics of CVID and IgGSD/SPAD patients
groups are summarized in Table 2. A total of 67 patients were
included in our study and are categorized according to the type
of PAD; 43 patients with CVID, 16 patients with IgGSD and 8
patients with SPAD. There is no familial relationship between
the patients. Thirty-nine patients received IVIG treatment at
doses between 20 and 80 g/4 weeks and 22 patients were on
subcutaneous Ig (ScIg) treatment at a dose of 19–53 g/4 weeks.
Six patients were not treated with Ig replacement therapy. A
significant difference in the number of patients receiving Ig
replacement therapy vs. patients receiving no Ig replacement
therapy was present between the CVID and IgGSD/SPAD group
TABLE 2 | Baseline characteristics of included patient groups.
Demographic
variable
CVID IgGSD/SPAD p-value
DIAGNOSIS
CVID
43 (64.2)
IgGSD 16 (23.9)
SPAD 8 (11.9)
Mean age at
evaluation, yr
47 (17.0) 53 (14.5) 0.099
Male 15 (34.9) 9 (37.5) 0.830
Receive Ig substitution 42 (97.7) 19 (79.2) 0.020
Data are mean (SD) or n (%). Ig, immunoglobulin; yr, years.
(Table 2). In all patients the serum CRP levels were within
normal range according to reference values from the AKC of
Erasmus MC.
Endocrine Disorders
All anterior pituitary and end-organ endocrine dysfunction
found in our cohort are summarized in Table 3.
Hypothalamic-Pituitary-Gonadal (HPG) Axis
In three out of 9 men with IgGSD/SPAD secondary
hypogonadism due to anterior pituitary dysfunction was
diagnosed. Male primary gonadal dysfunction was found in
one out of 15 men with CVID who presented with primary
testicular failure (i.e., low testosterone and high LH and FSH
levels) and was treated with testosterone replacement therapy.
There were no clinical indications for Klinefelter syndrome or
idiopathic granulomatous orchitis, and therefore, we did not
obtain karyotype or evaluate for antisperm antibodies.
Primary gonadal dysfunction (i.e., primary hypogonadism) in
women was identified in four out of 9 CVID patients (aged ≤40
years) that had premature ovarian failure based on low AMH,
low estrogen and high LH and FSH levels. Two of these patients
were treated with combined oral contraceptive pill. We did not
evaluate for adrenal antibodies or thyroid antibodies.
Hypothalamic-Pituitary-Thyroid (HPT) Axis
Hypothyroidism with normal TSH levels in one man out of 24
IgGSD/SPAD patients was considered to be due to secondary
hypothyroidism (i.e., a dysfunction of the anterior pituitary
gland) and was treated with thyroxine replacement therapy.
In four women thyroid dysfunction was found; one
woman out of 43 CVID patients demonstrated subclinical
hypothyroidism, defined as elevated TSH with normal
free thyroxine levels, whereas one of the 24 patients with
IgGSD/SPAD (female) had subclinical hypothyroidism including
the presence of thyroid antibodies. Autoimmune thyroiditis
was identified in two women with CVID; one had Graves’
disease and the other had granulomatous thyroiditis without the
presence of thyroid antibodies. The granulomatous thyroiditis
was detected with somatostatin receptor scintigraphy with
111In-pentetreotide (OctreoScan) and confirmed by fine-needle
aspiration biopsy of the thyroid gland. However, we cannot rule
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out that the hypothalamus nor the pituitary gland was affected by
granulomatous disease. This area is physiologically positive on
OctreoScan. However, patients with granulomatous hypophysitis
may benefit from high-dose corticosteroid therapy, which
was initiated in this patient when granulomatous thyroiditis
was diagnosed.
Hypothalamic-Pituitary-Adrenal (HPA) and
Somatotropic Axis
Provocative testing was performed when AI or GHD was
suspected. ITT was performed in 34 patients, metyrapone test in
9 patients and GHRH-arginine test in 8 patients.
In two out of 26 CVID patients partial secondary AI was
observed, where cortisol levels remained below 400–550 nmol/L
during ITT. In one of them hydrocortisone replacement therapy
was initiated during follow-up due to persistent low cortisol
levels. The other patient did not present with symptoms or
signs of hypocortisolism but cortisol levels remained suboptimal
during follow-up. Therefore, we provided stress instructions and
added to the medical record that hydrocortisone replacement
therapy was necessary in case of a medical emergency. One out of
18 patients with IgGSD/SPAD secondary AI was observed during
ITT and was treated with hydrocortisone replacement therapy.
Severe GHD was observed in one out of 23 patients with
CVID and in two out of 17 patients with IgGSD/SPAD. All three
patients were treated with GH replacement therapy. Moreover, in
one patient in the IgGSD/SPAD group mild GHD was observed.
Combined Endocrine Disorders
As was already mentioned above, some patients showed multiple
endocrine disorders. Combined anterior pituitary dysfunction
was detected in three men with IgGSD/SPAD; one had
severe GHD with secondary AI, the second mild GHD and
secondary hypogonadism, while the last patient had secondary
hypothyroidism and secondary hypogonadism.
In one woman with CVID we detected partial secondary AI
and primary hypogonadism, which is a combination of anterior
pituitary dysfunction and end-organ dysfunction. Combined
endocrine end-organ dysfunction was found in one woman with
CVID who presented with granulomatous thyroiditis as well as
primary hypogonadism.
MRI scans of the pituitary were performed in the three
patients with severe GHD and showed normal pituitary anatomy.
It should be noted that pituitary anatomy visualized byMRI is not
performed in other patients.
Genetic Analysis
To evaluate the involvement of NFKB2 in PAD patients with
endocrine dysfunctions, these patients (n = 16) were analyzed
by sequencing NFKB2 exon 22 and 23 (Table 3). No pathogenic
variant in the C-terminal region ofNFKB2 was detected in any of
these patients.
Additionally, 8 out of the 67 PAD patients were
investigated for pathogenic variants in PID-associated
genes. In one patient (Table 3; no. 1) a heterozygous
nuclear factor kappa beta inhibitor alpha (NFKBIA)-variant
(NM_020529.2(NFKBIA):c.554C>T, p.(Thr185Met)) with TA
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unknown significance was detected. This variant was
not identified in the unaffected father; the mother was
unavailable for testing. However, the minor allele frequency
in control populations (Genome Aggregation Database v2.1.1;
http://gnomad.broadinstitute.org/) was 0,026% (72 out of
282058 alleles) and functional assays in patients cells did
not show impairment of NFKB-activation and cytokine
production (data not shown). No other pathogenic variants
or candidates were detected in PID-associated genes in the
eight PAD patients.
DISCUSSION
To our knowledge, this is the first cross-sectional study on
the prevalence of endocrine disorders in adult PAD patients.
We not only reconfirmed previous findings demonstrating the
presence of endocrine disorders of anterior pituitary origin
in PAD patients, but we also found end-organ endocrine
dysfunction with or without anterior pituitary hormone
dysfunction. Moreover, the prevalence of endocrine disorders
was unexpectedly high in our patients with CVID, IgGSD,
and SPAD.
Our results confirm previous findings that severe GHD is
present in CVID patients (7, 11, 15, 21–23). We also observed
premature ovarian failure due to end-organ dysfunction in four
CVID patients, which was previously described in one case as
well (24).
In this study we observed for the first time co-existence of
partial secondary AI due to anterior pituitary dysfunction in
association with CVID. Moreover, it is also the first time we
observed primary testicular failure, subclinical hypothyroidism,
granulomatous thyroiditis and Graves’ disease due to end-organ
dysfunction in CVID patients. Noteworthy is that Graves’ disease
is a common autoimmune thyroid disease, but since patients
with CVID exhibit multiple autoimmune phenomena, we cannot
rule out Graves’ disease as a comorbidity in CVID. Also,
granulomatous complications are a well-known comorbidity
of CVID, particularly in the lungs, but these granulomas can
be present in all organs, which fits with the presence of
granulomatous thyroiditis in one of our CVID patients.
We show for the first time the occurrence of endocrine
disorders in adult patients with IgGSD/SPAD. The endocrine
disorders of anterior pituitary origin that we observed in the
IgGSD/SPAD group were secondary hypogonadism, secondary
hypothyroidism, secondary AI and mild and severe GHD. In the
latter, MRI scans showed normal pituitary anatomy. Therefore,
structural abnormalities (such as an expanding intrasellar mass)
or hypophysitis due to autoimmunity or auto-inflammatory
conditions are unlikely as causes for GH deficiency. A common
genetic cause may explain concomitant GH deficiency in PAD.
Moreover, chronic illness is also associated with suppressed
GH levels (30) and may account for the high incidence
of GH deficiency in PAD patients. Besides, we observed
subclinical hypothyroidism due to end-organ dysfunction in
the IgGSD/SPAD patients. Although, anterior pituitary hormone
deficiencies occurred even more in the IgGSD/SPAD group
than in the CVID group, these dysfunctions are not previously
described in literature.
PADs and disorders caused by deficiencies in anterior
pituitary function are both rare conditions. The high prevalence
of endocrine disorders in PAD patients as described in our study
may suggests that PADs and anterior pituitary dysfunction are
not two distinct phenomena in these patients, but could be both
the result of a single pathologic condition.
Previous studies have shown that variant(s) in NFKB2
(10, 12–16, 19–21, 26) could be considered as underlying
genetic defects resulting in both B cell immunodeficiency
and endocrine dysfunction. NFKB2 encodes the full-length
p100 protein and serves as central player of the non-
canonical NFKB signaling pathway, which has a critical role in
pituitary development, particularly in differentiation of ACTH-
producing corticotroph cells. Interestingly, all of the NFKB2
variants reported are near the C-terminus of the protein-
coding region of NFKB2, a region required for the correct
processing of the primary translation product (31, 32). It is
important to emphasize that the NFKB2 mutations described
so far showed heterogenic clinical expressivity (21) and are
associated with a variable penetrance (16), which makes
it difficult to predict the phenotype based on the genetic
alteration. However, in all our 16 patients with endocrine
dysfunctions no pathogenic variants in the C-terminal region
of NFKB2 was detected. Except for the NFKBIA-variant of
unknown significance in patient no. 1, we did not detect
other pathogenic variants in PID-associated genes in eight
PAD patients.
We did not identify pathological variation in the coding
sequence of the NFKB2 gene tested, but we believe that
the observations described support the existence of a disease
association possibly related to a common genetic link. Absence
of identification of sequence abnormalities in the open reading
frame of the NFKB2 gene tested might be due to the fact
that our study was limited to the coding exons of the gene.
Alternatively, it may be explained by the involvement of a
number of other currently identified or unknown genes. To
elucidate this issue, the possible common molecular cause for
combined endocrine- and immunodeficiencies is presently being
investigated in our cohort.
Endocrine disorders are not only found in PADs, but
are also common features in patients with other primary
immunodeficiency diseases (PIDs), such as type 1 diabetes
mellitus and thyroiditis in STAT1 gain-of function (GOF)
variant (3), type 1 diabetes mellitus and short statue in
STAT3 GOF variant (33), hypoparathyroidism in DiGeorge
syndrome (3) and hypo(para)thyroidism and AI in patients
with autoimmune polyendocrinopathy-candidiasis-ectodermal
dystrophy (APECED) (3). Future genetic studiesmay reveal more
common genetic pathways involved in immunodeficiency and
endocrine dysfunction.
Our report has several limitations. Firstly, we excluded
patients who were not able to temporarily discontinue their
use of corticosteroids, which interferes with provocative testing.
Therefore, the number of patients in which secondary AI was
found could be underestimated. Secondly, in our cohort almost
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all patients were on Ig replacement therapy during the study. The
way in which Ig replacement therapy exerts immunomodulatory
effects remains unclear, with many pathways, probably mutually
non-exclusive, in the innate and adaptive immune systems
being potentially targeted. Finally, we focused on the NFKB2
gene expression only in a selected group of PAD patients
with distinctive endocrine dysfunction. Moreover, PID gene
panel testing by WES was only performed in eight patients for
diagnostic purposes. From these patients, results were included
in the current study.
In this study we have observed a remarkably high prevalence
of pituitary and end-organ dysfunctions in adult patients with
CVID and we expand the phenotype by including IgGSD
and SPAD. However, it is not known until now how the
immunological and molecular defects in PADs contribute to
the development of endocrine disorders. Further genetic studies
in PADs may provide new insights into molecular and/or
autoimmune mechanisms that could result in these endocrine
comorbidities. Endocrine comorbidities in PAD may result in
a considerable health burden, we recommend that clinicians
consider endocrine disorders in PAD patients and screen for
endocrine dysfunction when appropriate.
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